Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator

被引:25
作者
Both, FL
Meneghini, L
Kerber, VA
Henriques, AT
Elisabetsky, E
机构
[1] Univ Fed Rio Grande Sul, Curso Posgrad Ciencias Farmaceut, Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande Sul, Dept Farmacol, Lab Etnofarmacol, Porto Alegre, RS, Brazil
[3] Univ Fed Parana, Dept Farm, BR-80060000 Curitiba, Parana, Brazil
来源
JOURNAL OF NATURAL PRODUCTS | 2005年 / 68卷 / 03期
关键词
D O I
10.1021/np049695y
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Behavioral effects of psychollatine, a new glycoside indole monoterpene alkaloid isolated from Psychotria umbellata, was investigated in models of anxiety, depression, memory, tremor, and sedation related to 5-HT and/or GABA neurotransmission. The GABA antagonist picrotoxin and the 5-HT2 antagonist ritanserin were used to examine the role of GABA and 5-HT2 receptors in psychollatine-induced effects. In the light/dark and hole-board models of anxiety, diazepam (0.75 mg/kg) and psychollatine (7.5 and 15 mg/kg) showed anxiolytic-like effect at doses that do not increase sleeping time nor alter spontaneous locomotor activity. The anxiolytic effect of psychollatine was prevented by prior administration of ritanserin, but not of picrotoxin, indicating that 5-HT2 but not GABA receptors are implicated. In the forced swimming model of depression, psychollatine (3 and 7.5 mg/kg) effects were comparable to the antidepressants imipramine (15 mg/kg) and fluoxetine (20 mg/kg). Psychollatine suppressed oxotremorine-induced tremors in all doses. In the step-down learning paradigm, diazepam (0.85 mg/kg), MK-801 (0.15 mg/kg), and psychollatine 100 mg/kg impaired the acquisition of learning and memory consolidation, without interfering with retrieval. It is concluded that the effects of psychollatine at the central nervous system involve serotonergic 5HT2(A/C) receptors.
引用
收藏
页码:374 / 380
页数:7
相关论文
共 38 条
[1]  
AZMITIA EC, 1991, J CLIN PSYCHIAT, V52, P4
[2]   Preclinical pharmacology of B-20991, a 5-HT1A receptor agonist with anxiolytic activity [J].
Beneytez, ME ;
Rodriguez, MLL ;
Rosado, ML ;
Morcillo, MJ ;
Orensanz, L ;
Fuentes, JA ;
Manzanares, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 344 (2-3) :127-135
[3]   Analgesic properties of umbellatine from Psychotria umbellata [J].
Both, FL ;
Kerber, VA ;
Henriques, AT ;
Elisabetsky, E .
PHARMACEUTICAL BIOLOGY, 2002, 40 (05) :336-341
[4]   Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice [J].
Bourin, M ;
Dhonnchadha, BAN ;
Colombel, MC ;
Dib, M ;
Hascoët, M .
BEHAVIOURAL BRAIN RESEARCH, 2001, 124 (01) :87-95
[5]   Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness [J].
Breese, GR ;
Knapp, DJ ;
Moy, SS .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2002, 26 (04) :441-455
[6]  
CELEUMANS DLS, 1985, PHARMACOPSYCHIATRY, V18, P303
[8]   Anxiolytic properties of the antipsychotic alkaloid alstonine [J].
Costa-Campos, L ;
Dassoler, SC ;
Rigo, AP ;
Iwu, M ;
Elisabetsky, E .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2004, 77 (03) :481-489
[9]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[10]   THE CONTRIBUTION OF BEHAVIORAL-STUDIES TO THE NEUROPHARMACOLOGY OF ANXIETY [J].
FILE, SE .
NEUROPHARMACOLOGY, 1987, 26 (7B) :877-886